Clinical Trial Update: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 study of CB-5083 in lymphoid hematologic malignancies, including relapsed and refractory multiple myeloma, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And Refractory Multiple Myeloma

Drugs mentioned

• CB-5083

Snippet

Sponsor: Cleave Biosciences, Inc. | Conditions: Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma | Phase 1 | Status: TERMINATED